<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01390077</url>
  </required_header>
  <id_info>
    <org_study_id>WLN02</org_study_id>
    <nct_id>NCT01390077</nct_id>
  </id_info>
  <brief_title>Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria</brief_title>
  <official_title>Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nitisinone is a potent inhibitor of the enzyme that catalyzes the formation of homogentisic&#xD;
      acid, and should be an even more logical treatment for alkaptonuria than for tyrosinemia, for&#xD;
      which it has been approved by the FDA.The objective of this research is to explore reported&#xD;
      age related differences in toxicity of nitisinone and its pharmacokinetic underpinnings and&#xD;
      to develop an optimal therapeutic requirement for a targeted population of presymptomatic&#xD;
      patients. The additional effect of mixtures of amino acids excluding tyrosine will be&#xD;
      explored to take advantage of protein synthesis to avoid elevations of tyrosine that would&#xD;
      otherwise limit the optimal dosage of nitisinone. The study is designed to treat patients and&#xD;
      find the optimal dosage of nitisinone to obtain maximal reduction in levels of homogentisic&#xD;
      acid and maintain safe levels of tyrosine.&#xD;
&#xD;
      The long term objective in the target population of pre-symptomatic patients is the&#xD;
      prevention of the characteristic effects on joint cartilage and tendons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study procedures are designed to:&#xD;
&#xD;
        1. Develop a method for nitisinone measurement via tandem mass spectrometry (MS/MS).&#xD;
&#xD;
        2. Determine whether differences between adult and children could be erased by employing a&#xD;
           dosage regimen based on m2 of body surface area as opposed to per kg of body weight, as&#xD;
           we have found in a recent study of dichloroacetate&#xD;
&#xD;
        3. Determine optimal dosage for reduction of urinary levels of homogentisic acid and&#xD;
           minimal elevation of plasma levels of tyrosine in the target population of&#xD;
           pre-symptomatic patients.&#xD;
&#xD;
        4. Determine optimal doses of Tyrex to prevent hypertyrosinemia and allow maximal reduction&#xD;
           in homogentisic acid.&#xD;
&#xD;
      Baseline studies will include ophthalmologic examinations, echocardiogram, X-rays of all&#xD;
      joints, MRI of selected joints when financially plausible; history and physical examinations&#xD;
      with emphasis on joints and tendons. Ideally MRI will be repeated at 12 month intervals&#xD;
      thereafter. Ophthalmologic exam, x-rays of the kidneys and prostate, and echocardiogram will&#xD;
      be repeated approximately every 12 months, depending on the age of the subject and the&#xD;
      nitisinone dose. Patients will be seen every 3 months for the first year, then at 6 month&#xD;
      intervals to month 36. The timing of the visits may be altered in response to modifications&#xD;
      of nitisinone and/or Tyrex doses.&#xD;
&#xD;
      Complete or near complete elimination of homogentisic acid excretion will be sought. Optimal&#xD;
      NTBC dosage would be judged to yield plasma concentration of tyrosine less than 1000 mmol/L&#xD;
      with the concomitant use of tyrosine free amino acid supplement. Dosage will be escalated or&#xD;
      reduced dependent on evidence of accumulation of nitisinone and urinary levels of HGA. The&#xD;
      maximum initial dose of nitisinone for adult and adolescent patients will be 0.2/mg/kg/day,&#xD;
      younger patients may require a larger dose; the standard dose in hypertyrosinemia is&#xD;
      1mg/kg/day, which will be tentatively used as the maximum dose for all populations.&#xD;
&#xD;
      Patients will be asked to collect first morning or 12 hour urine collections for homogentisic&#xD;
      acid and p-hydroxyphenyllactic acids and to monitor levels of tyrosine. Accumulation will be&#xD;
      tested for by repeated studies after 3 months of treatment. Trough levels for nitisinone will&#xD;
      be collected prior to and 5-7 days after dose increases and/or at months 6, 12, 18, 24 and&#xD;
      every 12 months.&#xD;
&#xD;
      The SF-36 Health Status Survey, a two page quality of life questionnaire which asks about&#xD;
      ADLs and emotional/social impacts of disease, will be completed by the patient or patient's&#xD;
      parent at baseline and every six months.&#xD;
&#xD;
      At any point during the study if the plasma tyrosine level is greater than 900umol/L the&#xD;
      amount of Tyrex or dietary protein intake may be modified, or the nitisinone dose may be&#xD;
      decreased. Protein Saver blood spot cards, which can be done in the patient's home and mailed&#xD;
      to our lab, will be given to the patients with instructions on blood collection to check the&#xD;
      tyrosine level after 5-7 days of the drug/dietary modifications. These steps-the dietary&#xD;
      modification with diet records if needed, addition or adjustment of Tyrex, adjustment of the&#xD;
      nitisinone dose, and repeat tyrosine analysis-will be repeated as necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Homogentisic Acid Excretion</measure>
    <time_frame>3-6 months</time_frame>
    <description>Urine homogentisic acid (umol/mmol creatinine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tyrosine Levels</measure>
    <time_frame>3-6 months</time_frame>
    <description>Plasma tyrosine (uM)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Alkaptonuria</condition>
  <arm_group>
    <arm_group_label>Nitisinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all subjects will receive open-label nitisinone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone</intervention_name>
    <description>Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.</description>
    <arm_group_label>Nitisinone</arm_group_label>
    <other_name>OrfadinÂ®,</other_name>
    <other_name>NTBC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of alkaptonuria with documented increased excretion of homogentisic acid&#xD;
&#xD;
          2. Willing and able to provide written, signed informed consent, or age appropriate&#xD;
             written assent and written informed consent by a legally authorized representative&#xD;
             after the study has been explained, prior to any research-related procedures.&#xD;
&#xD;
          3. Willing and able to be seen in the UCSD Clinical Center for Research or a satellite&#xD;
             site for the study visits&#xD;
&#xD;
          4. Possession of insurance coverage for standard of care procedures, clearly stated in&#xD;
             the consent forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Baseline tyrosine level above 250 mmol/mL&#xD;
&#xD;
          2. Baseline serum creatinine, creatine kinase, or transaminases 2x upper limit of normal&#xD;
&#xD;
          3. Baseline anemia or thrombocytopenia&#xD;
&#xD;
          4. Current participation in another investigational medication trial.&#xD;
&#xD;
          5. Pregnant or lactating women&#xD;
&#xD;
          6. Current keratopathy, contact use or uncontrolled glaucoma&#xD;
&#xD;
          7. History myocardial infarction or arrhythmia&#xD;
&#xD;
          8. History of pulmonary insufficiency&#xD;
&#xD;
          9. Psychiatric illness that may interfere with compliance or communication&#xD;
&#xD;
         10. Current malignancy or hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William L Nyhan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Suwannarat P, O'Brien K, Perry MB, Sebring N, Bernardini I, Kaiser-Kupfer MI, Rubin BI, Tsilou E, Gerber LH, Gahl WA. Use of nitisinone in patients with alkaptonuria. Metabolism. 2005 Jun;54(6):719-28.</citation>
    <PMID>15931605</PMID>
  </reference>
  <reference>
    <citation>Introne WJ, Perry MB, Troendle J, Tsilou E, Kayser MA, Suwannarat P, O'Brien KE, Bryant J, Sachdev V, Reynolds JC, Moylan E, Bernardini I, Gahl WA. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab. 2011 Aug;103(4):307-14. doi: 10.1016/j.ymgme.2011.04.016. Epub 2011 May 6.</citation>
    <PMID>21620748</PMID>
  </reference>
  <reference>
    <citation>Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL, Anderson PD, Huizing M, Anikster Y, Gerber LH, Gahl WA. Natural history of alkaptonuria. N Engl J Med. 2002 Dec 26;347(26):2111-21.</citation>
    <PMID>12501223</PMID>
  </reference>
  <reference>
    <citation>Gertsman I, Gangoiti JA, Nyhan WL, Barshop BA. Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome. Mol Genet Metab. 2015 Mar;114(3):431-7. doi: 10.1016/j.ymgme.2015.01.005. Epub 2015 Jan 29.</citation>
    <PMID>25680927</PMID>
  </reference>
  <results_reference>
    <citation>Gertsman I, Barshop BA, Panyard-Davis J, Gangoiti JA, Nyhan WL. Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria. JIMD Rep. 2015;24:13-20. doi: 10.1007/8904_2014_403. Epub 2015 Feb 10.</citation>
    <PMID>25665838</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2011</study_first_posted>
  <results_first_submitted>December 21, 2020</results_first_submitted>
  <results_first_submitted_qc>March 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2021</results_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>homogentisic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alkaptonuria</mesh_term>
    <mesh_term>Ochronosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nitisinone</title>
          <description>All subjects received open-label nitisinone, taken orally, supplied as a 2mg tablet. The starting dose was 2 mg once daily, and increased to 4, 6, or 8 mg, case-by-case.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>8 patients consented; only 7 continued to treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Nitisinone</title>
          <description>all subjects will receive open-label nitisinone&#xD;
Nitisinone: Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="31" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Homogentisic Acid Excretion</title>
        <description>Urine homogentisic acid (umol/mmol creatinine)</description>
        <time_frame>3-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HGA, Baseline</title>
            <description>Urine homogentisic acid (umol/mmol Cr), while taking no nitisinone</description>
          </group>
          <group group_id="O2">
            <title>HGA, 2 mg/d Nitisinone</title>
            <description>Urine homogentisic acid (umol/mmol Cr), while on nitisinone, 2 mg/d</description>
          </group>
          <group group_id="O3">
            <title>HGA, 4 mg Nitisinone</title>
            <description>Urine homogentisic acid (umol/mmol Cr), while on 4 mg/d nitisinone</description>
          </group>
        </group_list>
        <measure>
          <title>Homogentisic Acid Excretion</title>
          <description>Urine homogentisic acid (umol/mmol creatinine)</description>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1425.9" spread="678.3"/>
                    <measurement group_id="O2" value="113.1" spread="70.9"/>
                    <measurement group_id="O3" value="34.0" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tyrosine Levels</title>
        <description>Plasma tyrosine (uM)</description>
        <time_frame>3-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tyrosine, Baseline</title>
            <description>Plasma tyrosine (uM), while taking no nitisinone</description>
          </group>
          <group group_id="O2">
            <title>Tyrosine, 2 mg/d Nitisinone</title>
            <description>Plasma tyrosine (uM), while on nitisinone, 2 mg/d</description>
          </group>
          <group group_id="O3">
            <title>Tyrosine, 4 mg Nitisinone</title>
            <description>Plasma tyrosine (uM), while on 4 mg/d nitisinone</description>
          </group>
        </group_list>
        <measure>
          <title>Tyrosine Levels</title>
          <description>Plasma tyrosine (uM)</description>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" spread="14.8"/>
                    <measurement group_id="O2" value="668.7" spread="114.7"/>
                    <measurement group_id="O3" value="703.7" spread="120.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were monitored up to 3.5 years. Patients 1-3 were monitored over the course of 3-3.5 years, while patients 4-7 were monitored between 0.5 and 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nitisinone</title>
          <description>All subjects who participated in treatment received open-label nitisinone, taken orally, supplied as a 2mg tablet.&#xD;
The starting dose was 2 mg once daily, and increased to 4, 6, and 8 mg/d, case-by-case.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular irritation</sub_title>
                <description>Eye discomfort and blurry vistion</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Leo Nyhan, M.D., Ph.D.</name_or_title>
      <organization>University of California, San Diego</organization>
      <phone>(619)543-5337</phone>
      <email>wnyhan@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

